BIOBAM BIOINFORMATICS SL

Their core work

BioBam Bioinformatics is a Spanish bioinformatics software company based in Valencia that develops computational tools and analysis pipelines for life science research. In H2020 projects, they contribute specialist bioinformatics capacity — specifically genomic and epigenomic data analysis — to biomedical research consortia. Their work spans chromatin biology, epigenetic regulation, and increasingly the analysis of cancer-related datasets from single-cell sequencing experiments. They function as a technical service provider embedded in large training networks, delivering the computational infrastructure that enables wet-lab researchers to extract biological meaning from high-throughput data.

What they specialise in

How they've shifted over time

In the first project (ChroMe, 2016–2020), BioBam contributed to fundamental research on chromatin-metabolism interactions — broad mechanistic biology with no recorded disease focus. By their second project (INTERCEPT-MDS, 2021–2024), the work had sharpened considerably into disease interception: myelodysplastic syndrome, AML, clonal hematopoiesis, and single-cell sequencing entered the picture. This trajectory shows a company moving from foundational epigenomics toward clinically grounded cancer bioinformatics, likely driven by where MSCA training network funding was flowing in the early 2020s.

BioBam is tracking toward disease-specific bioinformatics for hematological cancers, with single-cell sequencing as their most current technical frontier — making them a relevant partner for consortia at the intersection of epigenomics, clinical genomics, and cancer early detection.

How they like to work

BioBam has participated in two projects without ever taking the coordinator role, positioning them clearly as a specialist technical contributor rather than a project driver. Both engagements were within MSCA Innovative Training Networks — large, multi-institution consortia — suggesting they are comfortable operating inside complex partnerships where their role is defined and bounded. Their 18 unique partners across 10 countries from just two projects indicates they join well-networked consortia rather than building tight bilateral relationships.

BioBam has collaborated with 18 distinct partners spanning 10 countries through two projects, a relatively broad network for an SME of their size and tenure. Their connections are distributed across European academic and research institutions typical of MSCA training network structures.

What sets them apart

BioBam occupies a specific niche as a private bioinformatics SME — not a university, not a hospital — contributing commercial-grade software and analysis capabilities to academic research consortia. This means they bring product discipline and tool reliability that purely academic partners cannot always offer. For a consortium needing bioinformatics capacity without hiring a postdoc, BioBam represents a ready, fundable partner with a track record in epigenomics and cancer genomics specifically.

Highlights from their portfolio

• INTERCEPT-MDS
  Their most recent and largest-funded project (€250,905), it places BioBam at the cutting edge of disease interception research combining epigenetics, single-cell sequencing, and hematological cancer — a high-visibility clinical genomics space.
• ChroMe
  Their entry into H2020, establishing core competence in chromatin biology that directly fed into their subsequent, more disease-focused work on MDS and AML.